SCHEMBL2289329

SCHEMBL2289329

COc1cc(O)ccc1C=CC(=O)c1sc(C)c(CC(C)C)c1C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSB P07858 5/20 0.54
CTSL P07711 4/20 0.54
TDP1 Q9NUW8 2/20 0.54
APP P05067 2/20 0.53
CYP1A1 P04798 1/20 0.50
CYP1B1 Q16678 1/20 0.50
CHRNA7 P36544 1/20 0.49
CAPN1 P07384 2/20 0.47
MAPT P10636 3/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
MAPK1 P28482 2/20 0.46
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 1/20 0.46
TP53 P04637 1/20 0.46
CYP3A4 P08684 1/20 0.46
HPGD P15428 1/20 0.46
CASP1 P29466 1/20 0.46
BRCA1 P38398 1/20 0.46
RECQL P46063 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2289324 0.79 CAPN1 (0.54) CTSBCTSLTDP1CHRNA7CAPN1
SCHEMBL2292106 0.76 F2 (0.45) MEN1KMT2ANPC1RAB9APKM
SCHEMBL13043179 0.73 CTSB (0.68) CTSBCTSLTDP1APPCHRNA7
SCHEMBL30545305 0.72 MAOA (0.74) CTSBCTSLTDP1APPCHRNA7
SCHEMBL12214355 0.71 CTSB (0.50) CTSBCTSLTDP1APPCYP1A1
SCHEMBL1859438 0.71 CTSB (0.50) CTSBCTSLTDP1APPCYP1A1
Echinatin SCHEMBL618086 0.71 CTSL (1.00) CTSBCTSLTDP1APPCYP1A1
Echinatin SCHEMBL7193984 0.71 CTSL (1.00) CTSBCTSLTDP1APPCYP1A1
Echinatin SCHEMBL29466900 0.71 CTSL (1.00) CTSBCTSLTDP1APPCYP1A1
SCHEMBL9234919 0.71 APP (1.00) CTSBCTSLTDP1APPCAPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1976512-B1 NOVEL THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2015-09-30 EP disclosed
US-8003800-B2 Thiophene derivatives as S1P1/EDG1 receptor agonists ACTELION PHARMACEUTICALS LTD. (CH) 2011-08-23 US disclosed
US-20100240717-A1 NOVEL THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS ACTELION PHARMACEUTICALS LTD. (CH) 2010-09-23 US disclosed
EP-1976512-A1 NOVEL THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS Actelion Pharmaceuticals Ltd. (CH) 2008-10-08 EP disclosed
WO-2007080542-A1 NOVEL THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2007-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240717-A1 NOVEL THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS S1PR3, S1PR1, S1PR2 CTSB 3863/4885CTSL 3968/4885TDP1 1373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.